← All stories
● Covered by 1 source · 1 reportMedium impact1 negative

FDA Warns GLP-1 Drugs May Increase Risk of Vision Loss Condition NAION

🔄 Updated 11d ago
New to BrevFeed? We gather this story from every outlet covering it into one summary — ranked by real-world impact, not just the latest headline — so you never miss what matters. What is BrevFeed? →

Key points

  • FDA mandates new warning for GLP-1 drugs.
  • Warning concerns non-arteritic anterior ischemic optic neuropathy (NAION).
  • NAION is a rare condition causing permanent vision loss.
  • A 2024 study suggested a link, but had limitations.

FDA Mandates New Warning

The Food and Drug Administration (FDA) has issued a drug safety communication requiring manufacturers of GLP-1 receptor agonist drugs to update their labels. This mandate applies to popular obesity and diabetes medications such as Ozempic, Wegovy, Zepbound, and Mounjaro. The new warning will highlight a "potential increased risk" of non-arteritic anterior ischemic optic neuropathy (NAION).

Understanding NAION

NAION is a rare eye condition characterized by restricted blood flow to the optic nerve. This restriction causes swelling and cell death, damaging the nerve and leading to abrupt vision loss, which can often be permanent. The condition affects between two and 10 people per 100,000 in the general population.

Potential Link and Challenges

The exact mechanism by which GLP-1 drugs might cause NAION is currently unknown. Establishing a definitive link is complicated by the condition's rarity and the fact that many patients taking GLP-1 drugs already have risk factors for NAION, including diabetes, cardiovascular disease, high blood pressure, high cholesterol, metabolic syndrome, and obstructive sleep apnea.

Research Findings and Limitations

A 2024 study by Harvard University researchers, published in JAMA Ophthalmology, was the first to suggest a connection. The study observed higher rates of NAION in patients taking semaglutide (Ozempic/Wegovy) compared to those on non-GLP-1 drugs. For instance, among diabetes patients, 8.9 percent on semaglutide developed NAION versus 1.8 percent in the non-GLP-1 group. However, the study had significant limitations, including potential selection bias due to all patients coming from a single referral center, which may affect the generalizability of the findings.

✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →

The daily brief

One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.

One email a day. Unsubscribe in one click, any time.

Today's brief

Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.

~4 min · 3 stories · Nov 21

▶ Play today's brief Listen on Spotify

New every morning, and the back catalogue is archived by date.

Reporting from

The FDA is requiring manufacturers of GLP-1 receptor agonist drugs, including Ozempic, Wegovy, Zepbound, and Mounjaro, to add a warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) on their labels. NAION is a rare eye condition caused by restricted blood flow to the optic nerve, which can lead to permanent vision loss. This action follows a 2024 study suggesting a link, though the data has limitations.